Search

everythinglearnresearchcommunity

for

Search:↓

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Certain topical drugs can regrow hair in mice.

JAK inhibitors may help treat alopecia areata and promote hair regrowth.

JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

The rash resolved after stopping ponatinib.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

A man developed skin issues from cancer medication, which improved with specific treatments.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

Ritlecitinib was generally well tolerated in children with alopecia areata.